The impact of neoadjuvant chemotherapy on surgical outcomes following autologous and implant-based immediate breast reconstruction: A systematic review and meta-analysis

Research output: Contribution to journalReviewResearchpeer-review

Standard

The impact of neoadjuvant chemotherapy on surgical outcomes following autologous and implant-based immediate breast reconstruction : A systematic review and meta-analysis. / Sabitovic, Ajla; Trøstrup, Hannah; Damsgaard, Tine Engberg.

In: Journal of Plastic, Reconstructive and Aesthetic Surgery, Vol. 87, 2023, p. 17-23.

Research output: Contribution to journalReviewResearchpeer-review

Harvard

Sabitovic, A, Trøstrup, H & Damsgaard, TE 2023, 'The impact of neoadjuvant chemotherapy on surgical outcomes following autologous and implant-based immediate breast reconstruction: A systematic review and meta-analysis', Journal of Plastic, Reconstructive and Aesthetic Surgery, vol. 87, pp. 17-23. https://doi.org/10.1016/j.bjps.2023.09.048

APA

Sabitovic, A., Trøstrup, H., & Damsgaard, T. E. (2023). The impact of neoadjuvant chemotherapy on surgical outcomes following autologous and implant-based immediate breast reconstruction: A systematic review and meta-analysis. Journal of Plastic, Reconstructive and Aesthetic Surgery, 87, 17-23. https://doi.org/10.1016/j.bjps.2023.09.048

Vancouver

Sabitovic A, Trøstrup H, Damsgaard TE. The impact of neoadjuvant chemotherapy on surgical outcomes following autologous and implant-based immediate breast reconstruction: A systematic review and meta-analysis. Journal of Plastic, Reconstructive and Aesthetic Surgery. 2023;87:17-23. https://doi.org/10.1016/j.bjps.2023.09.048

Author

Sabitovic, Ajla ; Trøstrup, Hannah ; Damsgaard, Tine Engberg. / The impact of neoadjuvant chemotherapy on surgical outcomes following autologous and implant-based immediate breast reconstruction : A systematic review and meta-analysis. In: Journal of Plastic, Reconstructive and Aesthetic Surgery. 2023 ; Vol. 87. pp. 17-23.

Bibtex

@article{dfd8916d3da64c12b6597a4fa44b2169,
title = "The impact of neoadjuvant chemotherapy on surgical outcomes following autologous and implant-based immediate breast reconstruction: A systematic review and meta-analysis",
abstract = "Background: The impact of neoadjuvant chemotherapy (NACT) on the complication rate after implant-based and autologous breast reconstruction remains unclear. The aim of this study was to systematically review and perform a meta-analysis of previously published studies on immediate breast reconstruction (IBR) in breast cancer patients treated with NACT compared with controls. Methods: PubMed and EMBASE were searched to identify studies assessing the impact of NACT on major and minor complications after IBR. The primary effect measures were relative risk (RR), 95% confidence interval (95% CI), and p-value. Results: Eight studies comprising 51,731 patients were included in the meta-analysis. Of these, 5161 patients received NACT and 46,570 patients did not receive NACT. In regard to major complications, NACT did not statistically significant increase the rate of reconstructive failure (RR = 1.35, 95% CI = 0.96–1.91, p = 0.09), the rate of mastectomy skin-flap necrosis (RR = 1.39, 95% CI = 0.61–3.17, p = 0.44), or the rate of reoperation (RR = 1.09, 95% CI = 0.87–1.37, p = 0.45). Regarding minor complications, NACT did not significantly increase the rate of wound complications (RR = 1.05, 95% CI = 0.87–1.28, p = 0.62). In a subgroup analysis of implant-based breast reconstruction following NACT, single-stage direct-to-implant (DTI) had a significantly lower implant failure rate compared with two-staged tissue expander/implant (TE/I) (RR = 0.43, 95% CI = 0.26–0.71, p = 0.0011). Conclusion: NACT did not increase the major or minor complication rate after IBR with either autologous tissue or implants. Thus, NACT and IBR should be considered safe procedures. The review of studies describing patients undergoing implant-based breast reconstruction following NACT could indicate that single-stage DTI was a safer procedure than two-staged TE/I. However, the association requires further evaluation.",
keywords = "Autologous breast reconstruction, Breast cancer, Implant-based breast reconstruction, Mastectomy, Neoadjuvant chemotherapy",
author = "Ajla Sabitovic and Hannah Tr{\o}strup and Damsgaard, {Tine Engberg}",
note = "Publisher Copyright: {\textcopyright} 2023 British Association of Plastic, Reconstructive and Aesthetic Surgeons",
year = "2023",
doi = "10.1016/j.bjps.2023.09.048",
language = "English",
volume = "87",
pages = "17--23",
journal = "Journal of plastic, reconstructive & aesthetic surgery : JPRAS",
issn = "1748-6815",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - The impact of neoadjuvant chemotherapy on surgical outcomes following autologous and implant-based immediate breast reconstruction

T2 - A systematic review and meta-analysis

AU - Sabitovic, Ajla

AU - Trøstrup, Hannah

AU - Damsgaard, Tine Engberg

N1 - Publisher Copyright: © 2023 British Association of Plastic, Reconstructive and Aesthetic Surgeons

PY - 2023

Y1 - 2023

N2 - Background: The impact of neoadjuvant chemotherapy (NACT) on the complication rate after implant-based and autologous breast reconstruction remains unclear. The aim of this study was to systematically review and perform a meta-analysis of previously published studies on immediate breast reconstruction (IBR) in breast cancer patients treated with NACT compared with controls. Methods: PubMed and EMBASE were searched to identify studies assessing the impact of NACT on major and minor complications after IBR. The primary effect measures were relative risk (RR), 95% confidence interval (95% CI), and p-value. Results: Eight studies comprising 51,731 patients were included in the meta-analysis. Of these, 5161 patients received NACT and 46,570 patients did not receive NACT. In regard to major complications, NACT did not statistically significant increase the rate of reconstructive failure (RR = 1.35, 95% CI = 0.96–1.91, p = 0.09), the rate of mastectomy skin-flap necrosis (RR = 1.39, 95% CI = 0.61–3.17, p = 0.44), or the rate of reoperation (RR = 1.09, 95% CI = 0.87–1.37, p = 0.45). Regarding minor complications, NACT did not significantly increase the rate of wound complications (RR = 1.05, 95% CI = 0.87–1.28, p = 0.62). In a subgroup analysis of implant-based breast reconstruction following NACT, single-stage direct-to-implant (DTI) had a significantly lower implant failure rate compared with two-staged tissue expander/implant (TE/I) (RR = 0.43, 95% CI = 0.26–0.71, p = 0.0011). Conclusion: NACT did not increase the major or minor complication rate after IBR with either autologous tissue or implants. Thus, NACT and IBR should be considered safe procedures. The review of studies describing patients undergoing implant-based breast reconstruction following NACT could indicate that single-stage DTI was a safer procedure than two-staged TE/I. However, the association requires further evaluation.

AB - Background: The impact of neoadjuvant chemotherapy (NACT) on the complication rate after implant-based and autologous breast reconstruction remains unclear. The aim of this study was to systematically review and perform a meta-analysis of previously published studies on immediate breast reconstruction (IBR) in breast cancer patients treated with NACT compared with controls. Methods: PubMed and EMBASE were searched to identify studies assessing the impact of NACT on major and minor complications after IBR. The primary effect measures were relative risk (RR), 95% confidence interval (95% CI), and p-value. Results: Eight studies comprising 51,731 patients were included in the meta-analysis. Of these, 5161 patients received NACT and 46,570 patients did not receive NACT. In regard to major complications, NACT did not statistically significant increase the rate of reconstructive failure (RR = 1.35, 95% CI = 0.96–1.91, p = 0.09), the rate of mastectomy skin-flap necrosis (RR = 1.39, 95% CI = 0.61–3.17, p = 0.44), or the rate of reoperation (RR = 1.09, 95% CI = 0.87–1.37, p = 0.45). Regarding minor complications, NACT did not significantly increase the rate of wound complications (RR = 1.05, 95% CI = 0.87–1.28, p = 0.62). In a subgroup analysis of implant-based breast reconstruction following NACT, single-stage direct-to-implant (DTI) had a significantly lower implant failure rate compared with two-staged tissue expander/implant (TE/I) (RR = 0.43, 95% CI = 0.26–0.71, p = 0.0011). Conclusion: NACT did not increase the major or minor complication rate after IBR with either autologous tissue or implants. Thus, NACT and IBR should be considered safe procedures. The review of studies describing patients undergoing implant-based breast reconstruction following NACT could indicate that single-stage DTI was a safer procedure than two-staged TE/I. However, the association requires further evaluation.

KW - Autologous breast reconstruction

KW - Breast cancer

KW - Implant-based breast reconstruction

KW - Mastectomy

KW - Neoadjuvant chemotherapy

U2 - 10.1016/j.bjps.2023.09.048

DO - 10.1016/j.bjps.2023.09.048

M3 - Review

C2 - 37804643

AN - SCOPUS:85172871397

VL - 87

SP - 17

EP - 23

JO - Journal of plastic, reconstructive & aesthetic surgery : JPRAS

JF - Journal of plastic, reconstructive & aesthetic surgery : JPRAS

SN - 1748-6815

ER -

ID: 390186626